I will be very happy if OncoCyte's IPO goes as well as AST's.
Dendritic cancer vaccines, stem cell spine trials for paralysis, three different cancer diagnostic products about to be released in major hospitals....what don't you like about this company!
Thank you Dr. West, will make a nice Christmas present!
Mothership here, 2016 OncoCyte/BTX products/revenues start to hit market. AST cancer vaccine and or spine trials will be in final stages. My advice: buy now before BTX shares are more like $20 range next year.
Good insight, amazing all that has gotten done in eight years with no revenues, just goes to show how much investors and partners believe in this company.
Proof is in the partners:
CORPORATE PARTNERSHIPS & LICENSING
GE Healthcare (December 2014) »
Abcodia Ltd. (September 2014) »
Cancer Research UK (September 2014) »
University of Wisconsin and Louvain University (August 2014) »
Cornell University (May 2014) »
California Institute of Regenerative Medicine (May 2014) »
Jade Therapeutics (September 2013) »
University of California, Los Angeles (April 2013) »
Wistar Institute (January 2012) »
USCN Life Science, Inc. (December 2011) »
Cornell University (September 2011) »
California Institute of Regenerative Medicine (November 2010) »
Teva Pharmaceutical Industries, Ltd. (October 2010) »
Millipore (July 2009) »
Ocata Therapeutics, Inc. (formerly Advanced Cell Technology, Inc.) (July 2008) »
Wisconsin Alumni Research Foundation (January 2008) »
Hospira, Inc. (U.S.) / CJ Health Corporation (December 2006) »
CJ Health Corporation (April 2003) »
Abbott Laboratories, Inc. (April 1997) » Less